Aligos Therapeutics, Inc.

Name: Aligos Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

ALGSNasdaqCIK 1799448HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026

Operating income−$1.9m, Q2 FY2026

Net income−$1.5m, Q2 FY2026

Aligos Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	1.1	0.7	0.7	1.1	1.3	0.6	0.3	1.0	0.7	0.2	2.8	0.0
Research and development	$m	15.9	22.3	16.4	21.1	16.8	16.0	14.5	14.0	23.9	17.0	23.4	24.1
Operating income	$m	(19.1)	(26.0)	(22.0)	(26.4)	(20.1)	(20.6)	(19.2)	(18.6)	(28.4)	(21.8)	(26.9)	(1.9)
Income tax	$m	0.0	(0.0)	0.0	0.2	0.1	0.0	0.0	0.2	0.1	0.0	0.3	2.8
Net income	$m	(18.0)	(27.9)	(34.9)	5.1	(19.3)	(82.2)	43.1	(15.9)	(31.5)	(19.9)	(23.0)	(1.5)
Diluted EPS	$ per share	(10.37)	not reported	(5.58)	0.81	(3.07)	not reported	(2.11)	(1.53)	(3.04)	not reported	(2.21)	(0.14)
Basic EPS	$ per share	(10.37)	not reported	(5.58)	0.81	(3.07)	not reported	5.12	(1.53)	(3.04)	not reported	(2.21)	(0.14)

Balance sheet

Cash and equivalents$30.4m, Q2 FY2026

Shareholders' equity$31.9m, Q2 FY2026

Aligos Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	70.4	136	24.2	45.1	35.3	37.0	73.8	18.7	41.9	18.3	30.0	30.4
Current assets	$m	74.6	141	118	99.6	79.8	62.1	143	128	103	82.9	59.6	62.1
Total assets	$m	85.9	152	128	109	88.4	70.1	151	135	110	88.5	64.6	66.3
Current liabilities	$m	22.5	23.9	18.9	23.6	21.0	21.7	18.9	20.3	22.0	21.2	23.3	28.3
Total liabilities	$m	31.0	59.4	68.1	41.6	38.3	99.1	34.3	32.8	37.9	35.0	32.8	34.4
Shareholders' equity	$m	54.8	92.1	59.8	67.2	50.1	(29.0)	116	102	71.8	53.5	31.8	31.9

Cash flow

Operating cash flow−$24.9m, Q2 FY2026

Aligos Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(20.3)	(22.7)	(22.7)	(19.5)	(20.1)	(18.4)	(20.9)	(15.5)	(24.3)	(21.7)	(23.1)	(25.0)
Capital expenditure	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)10.43m, Q2 FY2026

Aligos Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	42.8	42.9	43.2	1.7	6.2	6.3	6.3	8.7	10.4	10.4	10.4	10.4

Shares outstanding: 42.61m at Aug 4, 2021, from the cover of the 10-Q filed Aug 5, 2021.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.